10 straight weeks of RED ?
Recent RS to help meet the NASDAQ minimum bid requirement, yet post reverse split we are right back near $1/share.
Float is around 4.2 million shares. Today ADTX traded 4.68 million shares.
Short interest is exceptionally high. I was hoping a catalyst would occur today or tomorrow to force them to BEGIN TO cover.
Thoughts anyone?
Recent RS to help meet the NASDAQ minimum bid requirement, yet post reverse split we are right back near $1/share.
Float is around 4.2 million shares. Today ADTX traded 4.68 million shares.
Short interest is exceptionally high. I was hoping a catalyst would occur today or tomorrow to force them to BEGIN TO cover.
Thoughts anyone?
Recent ADTX News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2026 08:21:24 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2026 09:03:44 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/20/2026 08:31:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:20:52 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/15/2026 08:20:06 PM
- Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-27 Reverse Stock Split Effective at the Open of Trading on May 18, 2026 • Business Wire • 05/14/2026 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2026 08:20:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/01/2026 08:35:47 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/23/2026 08:30:42 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/22/2026 04:15:21 AM
- Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics’ RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients • Business Wire • 04/20/2026 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/14/2026 12:00:13 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 04/11/2026 01:49:19 AM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 04/07/2026 08:02:58 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/03/2026 08:37:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 01:13:36 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2026 08:35:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 12:00:37 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/27/2026 09:02:12 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/24/2026 09:21:36 PM
- Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer • Business Wire • 03/19/2026 12:15:00 PM
- Aditxt Acquires Ignite Proteomics to Expand Precision Oncology Capabilities • IH Market News • 03/13/2026 03:36:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2026 12:35:24 PM
- Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection • Business Wire • 03/13/2026 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:30:35 PM
